Purinex was as a drug discovery and evolution company located in Syracuse, New York. “The company sought to commercialize therapeutic compounds based on its purine drug-development platform.” The company evolved procedure for making small molecules that acted as selective agonists or antagonists. The company consisted of 14 employees and the company has a chemistry laboratory, and 35 pending patents in the purine field. During 2004, the company promised two drug treatment: the first one for diabetes and the second one for sepsis.
The pharmaceutical industry was known one of the most effective economic sector and have more than 530$ billion in sales. The company grew faster than most other divisions of the economic, but they forecasted the …show more content…
“The partnership, if secured, would enable Purinex to develop one of its leading compounds into drug for the treatment of one of the world’s deadliest and most widespread diseases.” The problem is the company had only enough cash and had not sales. The CFO of Purinex, Gilad Harpaz thought that if a partnership deal survive, the Purinex might be in perfect situation to fulfill its work. “Harpaz thought that the company could either try secure financing now or wait until struck a partnership deal. The company had a lot of comprehensive technologies was under evolution, and had a suitable partnership deal one for sepsis and the second one is for diabetes. If the partnership was happened, Harpaz estimated 60 % would be for sepsis. However, if this did not happen, they would search for other company for diabetes application. Harpaz was worried about the company because it had only 700,000 available and burn rate 60,000. So, the company had three possibilities to do: 1- Venture capital round, 2- Wait six months, and 3- Angel …show more content…
Also, the owners of Purinex would keep complete control of the company and it estimated to be valued at 25 million. This is regarded as the highest evaluation between the angle round and venture capital round. If the deal was failed to happen, the company should force itself into a down round, and makes the valuation for the company decline to 8 million or 5 million. This option should be accepted if the deal is
The pharmaceutical industry was known one of the most effective economic sector and have more than 530$ billion in sales. The company grew faster than most other divisions of the economic, but they forecasted the …show more content…
“The partnership, if secured, would enable Purinex to develop one of its leading compounds into drug for the treatment of one of the world’s deadliest and most widespread diseases.” The problem is the company had only enough cash and had not sales. The CFO of Purinex, Gilad Harpaz thought that if a partnership deal survive, the Purinex might be in perfect situation to fulfill its work. “Harpaz thought that the company could either try secure financing now or wait until struck a partnership deal. The company had a lot of comprehensive technologies was under evolution, and had a suitable partnership deal one for sepsis and the second one is for diabetes. If the partnership was happened, Harpaz estimated 60 % would be for sepsis. However, if this did not happen, they would search for other company for diabetes application. Harpaz was worried about the company because it had only 700,000 available and burn rate 60,000. So, the company had three possibilities to do: 1- Venture capital round, 2- Wait six months, and 3- Angel …show more content…
Also, the owners of Purinex would keep complete control of the company and it estimated to be valued at 25 million. This is regarded as the highest evaluation between the angle round and venture capital round. If the deal was failed to happen, the company should force itself into a down round, and makes the valuation for the company decline to 8 million or 5 million. This option should be accepted if the deal is